Stablix, Inc.
@StablixInc
Followers
83
Following
9
Media
3
Statuses
10
Pioneering transformative medicines for targeted deubiquitination therapeutics (TPT)
New York, NY and Boston, MA
Joined June 2021
Check out the @WuXi_AppTec “BOLD: Innovation That Matters” event happening today. Hear from our CSO @EddineSaiah on how we’re expanding the definition of druggability by unlocking the power of targeted protein #deubiquination. Tune in: #TakingBOLDAction
0
1
2
How are we #TakingBOLDAction to pioneer targeted protein #deubiquitination therapeutics?. Tomorrow, Chief Scientific Officer @EddineSaiah will share how we're aiming to redefine #druggability during @WuXi_AppTec’s “BOLD: Innovation That Matters." Register:
0
2
3
Why is our collaboration with @VertexPharma the perfect match? Our CEO, Tony Kingsley, explains:. “We bring DUB biology and chemistry, they bring the target disease and disease expertise.”. Check out the full article by @Nicole_DeFeudis of @endpts here! 👇.
endpoints.news
Roughly two years after Stablix embarked on a mission to stabilize certain proteins whose insufficiency leads to disease, Vertex Pharmaceuticals announced it’s coming along for the ride. Stablix and...
0
0
5
We’re thrilled to announce our collaboration with @VertexPharma to discover & develop #TPS (targeted protein stabilization) therapeutics. Learn how we’re exploring the potential of targeted protein #deubiquitination for patients in need of breakthroughs:
0
2
7
Our COO and co-founder, Kevin Sprott, is thrilled to speak in a panel discussion at the #wellsfargo 2023 Targeted Protein Degradation (#TPD) Virtual Summit tomorrow (2p EST), as we establish a new paradigm for restoring protein function.
globenewswire.com
NEW YORK, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel...
0
1
0
Exciting start to the week. We are thrilled to welcome Tony Kingsley!.
Tony Kingsley is taking charge at Stablix, a biotech startup out of Versant that announced a $63 million launch raise just a couple of months before the biotech exec found the exit at Scholar Rock.
0
0
1
RT @lisamjarvis: Versant-backed Stablix has launched to use heterobifunctional moecules to tap into the ubiquitin-proteasome system--but th….
cen.acs.org
The biotech firm aims to develop bifunctional small molecules for rare diseases, cancer, and immunology
0
2
0
We are excited to announce our Series A launch to pioneer this new therapeutic white space and address a number of devastating diseases! #targetedproteinstabilization #stablix #TPS.
businesswire.com
Stablix Therapeutics, a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS), today announced a $63 million Series A financing ...
0
0
4